Sterling Drug Inc.

Other

George Y Lesher

Baldev Singh

Chester J Opalka, Jr

Donald F Page

William B Dickinson

Monte D Gruett

Ruth P Brundage

Richard E Philion

Sol J Daum

Ruthann M McGarry

Stanley C Laskowski

Michael Reuman

Edward R Bacon

Denis M Bailey

Joseph C Collins

Philip M Carabateas

Thomas E D'Ambra

Karl O Gelotte

Andrew W Zalay

Alexander R Surrey

Gee-Hong Kuo

Chester Joseph Opalka

Fluorinated 1- cyclopropyl-7-(substituted-pyridinyl)-1,4-dihydro-4-oxo-3-quinolinecarboxy lic acids of the formula ##STR1## wherein R is hydrogen, R' and R' are hydrogen or fluoro, and Z is 3- or 4-pyridinyl substituted by alkyl groups or substituted alkyl groups, are superior antibacterial agents. They are prepared via a coupling reaction between the corresponding esters (R=alkyl) having a halo group in the 7-position and a substituted (trialkylstannyl)-pyridine.

Pyridinyl-quinolone compounds, their preparation and use

Fluorinated 1-cyclopropyl-7-(substituted-pyridinyl)-1,4-dihydro-4-oxo-3-quinolinecarbo xylic acids of the formula ##STR1## wherein R is hydrogen, R' and R' are hydrogen or fluoro, or other groups and Z is 3- or 4-pyridinyl substituted by alkyl groups or substituted alkyl groups, are superior antibacterial agents. They are prepared via a coupling reaction between the corresponding esters (R=alkyl) having a halo group in the 7-position and a substituted (trialkylstannyl)pyridine.

Novel 1,3-dihydro-2H-imidazo[4,5-b]pyridin-2-ones having an aryl or heteroaryl group in the 6-position, useful as phosphodiesterase inhibitors, are prepared by reacting a 2-amino-5-(aryl or heteroaryl)pyridine-3-carboxylic acid with diphenylphosphoryl azide. The compounds are of the formula ##STR1## where R.sub.1 and R.sub.3 are hydrogen or lower-alkyl, R.sub.5 is lower-alkyl or fluorinated lower-alkyl, and Ar is 4- or 3-pyridinyl, or phenyl or substituted phenyl.

Imidazopyridines, their preparation and use

N-[(heterocycle)alkyl]-3,4 (or 4,5)-diaryl-1H-pyrazole-1-acetamides and pyrazole-1-propanamides, useful for treating cardiac arrhythmias in mammals, are prepared by reacting a lower-alkyl ester of pyrazole-1-acetic or propanoic acid with an appropriate (heterocycle-alkyl) amine or by reacting a pyrazole-1-acetic or propanoic acid with an appropriate (heterocycle-alkyl)amine.

N-(heterocycle)alkyl)-1H-pyrazole-1-alkanamides as antiarrhythmic

Fluorinated 10-(2,6-dimethyl-4-pyridinyl)-3-methyl-7-oxo-2,3-dihydro-7H-pyrido[1,2,3-d e][1,4]benzoxazine-6-carboxylic acids and -benzothiazine-6-carboxylic acids of the formula ##STR1## wherein R is hydrogen, R' is hydrogen or fluoro, R' is alkyl of 1-3 carbon atoms and X is O or S are superior antibacterial agents.

Tricyclic-pyridinylquinoline compounds, their preparation and use

5-[1H-(5-membered-N-aromatic-heteryl)-1-yl]-7-R'-1,6-naphthyridin-2(1H)-one s (formula I) or salts thereof are useful as cardiotonic agents. Also shown as intermediates are 5-X-7-R'-1,6-naphthyridin-2(1H)-ones (formula II) or salts thereof, where X is bromo, chloro or hydrazino, 2-[2-(di-lower-alkylamino)ethenyl]-1,6-dihydro-6-oxo-3-pyridinecarbonitril e (formula III), and 2-[2-(di-lower-alkylamino)-2-propenyl]-6-methoxy-3-pyridinecarbonitrile (formula IIIa). Processes shown include the preparation of I from II, preparation of II from III or IIIa and the preparation of III from 1,6-dihydro-2-methyl-6-oxo-3-pyridinecarbonitrile, and the preparation of IIIa from 6-methoxy-2-methyl-3-pyridinecarbonitrile.

5-[1H-(5-membered-N-aromatic heteryl)-1-yl]-1,6-naphthyridin-2(1H)-ones

1-Ethyl-6-fluoro-1,4-dihydro-7-(2,6-dimethyl-4-pyridinyl)-4-oxo-3-quinoline carboxylic acid (Win 52,522) or salt thereof, a highly potent antibacterial agent, is prepared by nitrating the corresponding 6-desfluoro compound (Win 35,439) to produce the corresponding 6-nitro compound, reducing the latter compound to produce the corresponding 6-amino compound and converting the 6-amino via its diazonium salt to said 6-fluoro compound (Win 52,522). Comparative in vitro and in vivo antibacterial test data are provided to demonstrate the uniqueness of Win 52,522 as a highly potent antibacterial agent having a broad spectrum of antimicrobial activity.

1-ethyl-6-fluoro-1,4-dihydro-

5-[1H-(5-membered-N-aromatic-heteryl)-1-yl]-7-R'-1,6-naphthyridin-2(1H)-one s (formula I) or salts thereof are useful as cardiotonic agents. Also shown as intermediates are 5-X-7-R'-1,6-naphthyridin-2(1H)-ones (formula II) or salts thereof, where X is bromo, chloro or hydrazino, 2-[2-(di-lower-alkylamino)ethenyl]-1,6-dihydro-6-oxo-3-pyridinecarbonitril e (formula III), and 2-[2-(di-lower-alkylamino)-1-propenyl]-6-methoxy-3-pyridinecarbonitrile (formula IIIa). Processes shown include the preparation of I from II, preparation of II from III or IIIa and the preparation of III from 1,6-dihydro-2-methyl-6-oxo-3-pyridinecarbonitrile, and the preparation of IIIa from 6-methoxy-2-methyl-3-pyridinecarbonitrile.

1,6-dihydro-6-oxo-3-pyridinecarbonitriles, intermediates for cardiotonic

5-X-7-R'-1,6-Naphthyridine-2(1H)-ones (formula II) or salts thereof, where X is bromo, chloro or hydrazino and R' is hydrogen or methyl, which are useful as cardiotonic agents.

1,6-naphthyridine-2(1H)-ones and their use as cardiotonic agents

3-Z-5-(Q-CO)-6-methyl-2(1H)-pyridinones (I) or salts thereof, where Q is 2(or 3)-furanyl or 2(or 3)-thienyl when Z is hydrogen or cyano, or where Q is 4(or 3)-pyridinyl or 4(or 3)-pyridinyl having one or two methyl substituents only when Z is cyano, are useful as cardiotonic agents. Processes for preparing said compounds (I) are shown.

Cardiotonic 5-(heterylcarbonyl)-pyridones

2-[2-(di-lower-alkylamino-1-propenyl]-6-methoxy-3-pyridinecarbonitriles, useful as intermediates for cardiotonic agents.

2-[2-(di-lower-alkylamino)-1

4-R'-5-Q-1,6-naphthyridin-2(1H)-ones (I), where R' is hydrogen or methyl and Q is hydroxymethyl, 1-hydroxyethyl alkanoyloxymethyl or 1-alkanoyloxyethyl, are produced by first reacting 4-R'-5-acetyl(or n-propanoyl)-6-[2-(di-lower-alkylamino]-2(1H)-pyridinone [III] with hydroxylamine or salt thereof to produce 4-R'-5-Q'-1,6-naphthyridin-2(1H)-one-6-oxide (II), where R' is defined as above and Q' is methyl or ethyl; next reacting II with an alkanoic anhydride to produce I where Q is alkanoyloxymethyl or 1-alkanoyloxyethyl; and, then hydrolyzing said alkanoyloxymethyl or -ethyl compound to produce I where Q is hydroxymethyl or 1-hydroxyethyl. Also shown is the cardiotonic use of II and I where Q is hydroxymethyl, 1-hydroxyethyl or alkanoyloxymethyl.

5-methyl(or ethyl)-1,6-naphthyridin-2(1H)-one 6-oxides, their

Disclosed and claimed is the cardiotonic use of 1-R.sub.1 -5-(3-R'-4-R'-phenyl)-6-R-2(1H)-pyridinones (II), where R.sub.1 is hydrogen, lower-alkyl or lower-hydroxyalkyl, R is lower-alkyl or hydrogen, and, R' and R' are each hydrogen, amino or hydroxy, at least one of R' or R' being other than hydrogen, or where R' is nitro when R' is hydroxy, or pharmaceutically acceptable acid-addition salts thereof where at least one of R' and R' is amino. Also disclosed and claimed are 1-R.sub.1 -5-(3-R'-4-R'-phenyl)-6-R-2(1H)-pyridinones (I), where R.sub.1, R' and R' are defined as above and R is lower-alkyl and acid-addition salts thereof where at least one of R' and R' is amino. Also shown and claimed is the process which comprises reacting 1-R.sub.1 -1,2-dihydro-2-oxo-5-(3-R'-4-R'-phenyl)-6-R-nicotinonitrile, where R.sub.1 and R are defined as above for II, R' is hydrogen, hydroxy, methoxy or amino and R' is hydroxy, methoxy or hydrogen, preferably at least one of R' and R' being methoxy, or where R' is nitro and R' is hydrogen or methoxy, preferably methoxy, with 85% phosphoric acid to produce 1-R.sub.1 -5-(3-R'-4-R'-phenyl)-6-R-2(1H)-pyridinone, where R.sub.1 and R are defined as above for II, R' is hydrogen, hydroxy or amino and R' is hydroxy or hydrogen, at least one of R' and R' being hydroxy, or where R' is nitro and R' is hydroxy.

Preparation of 5-(hydroxy- and/or

3-Q-4-R.sub.2 -5-(2-Q'-5-R.sub.3 -4-thiazolyl)-6-R.sub.1 -2(1H)-pyridinones (I), where R.sub.1 is alkyl having from one to four carbon atoms, R.sub.2 is hydrogen or methyl, R.sub.3 is hydrogen or alkyl having from one to three carbon atoms, Q is amino, carbamyl, carboxy, cyano or hydrogen, and Q' is alkyl having from one to four carbon atoms, amino or R.sub.4 NH where R.sub.4 is alkyl having from one to four carbon atoms, or acid-addition salts thereof where at least one of Q and Q' is amino or Q' is R.sub.4 NH, are useful as cardiotonics (I where Q is amino, cyano or hydrogen) and/or as intermediates (I where Q is cyano, carbamyl or carboxy). Also shown as intermediates are 1,2-dihydro-4-R.sub.2 -5-[R.sub.3 CH(Br)CO]-6-R.sub.1 -2-oxo-3-pyridinecarbonitriles (II), and, also, processes for preparing I and II.

5-.alpha.-bromoalkanoyl-2-oxo-3-pyridinecarbonitriles

3-(NB)-4-Q-6-PY-pyridazines (I) or salts thereof, which are useful as cardiotonics, are prepared by reacting a 3-halo-4-Q-6-PY-pyridazine with an amine, H-NB, to produce I, where PY is 4- or 3-pyridinyl or 4- or 3-pyridinyl having one or two lower-alkyl substituents and Q is cyano when NB is NHCH.sub.3 or N(CH.sub.3).sub.2, or Q is carbamyl when NB is NHCH.sub.3, or Q is hydrogen when NB is N(CH.sub.3).sub.2. Cardiotonic use of said 3-(NB)-4-Q-6-PY-pyridazines or salts is shown.

Growing community of inventors

Schodack, NY, United States of America

George Y Lesher